Use of Antiretrovirals for HIV Prevention: What Do We Know and What Don’t We Know?
- 798 Downloads
Pre-exposure prophylaxis (PrEP), in which HIV uninfected persons with ongoing HIV risk use antiretroviral medications as chemoprophylaxis against sexual HIV acquisition, is a promising new HIV prevention strategy. Proof-of-concept that PrEP, as oral or vaginal topical tenofovir-based products, protects against sexual HIV acquisition has been demonstrated in clinical trials conducted among men who have sex with men and heterosexual men and women. The degree of HIV protection in these trials was strongly related to the level of adherence to PrEP. Many questions are yet unanswered – including how to motivate uptake of and sustain adherence to PrEP for HIV prevention, how much PrEP use is enough to achieve HIV protection, and the potential of “next-generation” PrEP agents to improve on this effective technology.
KeywordsAntiretroviral medications Chemoprophylaxis Global epidemic HIV/AIDS HIV prevention Pre-exposure prophylaxis (PrEP) Sexual HIV transmission
The authors acknowledge the funding support of US National Institutes of Health (R01 MH095507, R01 AI064002, R01 AI062333), the Bill & Melinda Gates Foundation (grants 47674 and 48162) and Gladstone Institutes.
The authors have conducted research studies related to pre-exposure prophylaxis for HIV prevention supported with grant funding from the US National Institutes of Health, the US Agency for International Development, the Bill & Melinda Gates Foundation, and the US Centers for Disease Control and Prevention. Gilead Sciences provided study medication for these studies but did not provide funding to the authors or their institutions.
Conflict of Interest
Jared Baeten declares that he has no conflict of interest.
Robert Grant declares that he has no conflict of interest.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.Baeten J, Celum C. Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis. Annu Rev Med. 2012;27:27.Google Scholar
- 3.•• Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505. This randomized clinical trial provided definitive evidence that use of antiretroviral treatment by HIV-infected persons reduces the risk of HIV transmission to sexual partner. Use of antiretroviral medications for treatment of HIV infected persons to reduce infectiousness and PrEP for HIV uninfected persons to reduce susceptibility are complementary prevention strategies.PubMedCrossRefGoogle Scholar
- 5.•• Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410. This randomized clinical trial demonstrated that oral PrEP using daily oral FTC/TDF and daily oral TDF alon, was efficacious for prevention of HIV acquisition in both heterosexual men and women who were in HIV serodiscordant partnerships.PubMedCrossRefGoogle Scholar
- 6.•• Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99. This randomized clincal trial demonstrated that oral PrEP, using daily oral FTC/TDF, was efficacious for prevention of HIV acquisition in men who have sex with men.PubMedCrossRefGoogle Scholar
- 7.•• Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423–34. This randomized clinical trial provides additional evidence of the efficacy FTC/TDF PrEP for HIV prevention among heterosexuals.PubMedCrossRefGoogle Scholar
- 8.UNAIDS. World AIDS Day Report 2012.Google Scholar
- 9.UNAIDS/WHO. AIDS Epidemic Update 2009.Google Scholar
- 24.Kashuba AD, Patterson KB, Dumond JB, Cohen MS. Pre-exposure prophylaxis for HIV prevention: how to predict success. Lancet. 2011;6:6.Google Scholar
- 26.• Abdool Karim SS, Kashuba AD, Werner L, Abdool Karim QA. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet. 2011;378:279–81. This report details the relationship between tenofovir exposure and HIV protection in the CAPRISA 004 study.CrossRefGoogle Scholar
- 27.•• Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168–74. This randomized clinical trial demonstrated that 1 % tenofovir vaginal gel, when used with coitus, reduced HIV risk in South African women.PubMedCrossRefGoogle Scholar
- 32.•• Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411–22. This randomized clinical trial among women from Kenya, South Africa, and Tanzania failed to demonstration HIV protection using emtricitabine/tenofovir oral PrEP, likely as a result of low PrEP use.PubMedCrossRefGoogle Scholar
- 33.National Institute of Allergy and Infectious Diseases (NIAID). NIH modifies ‘VOICE’ HIV prevention study in women. 2011. http://www.nih.gov/news/health/sep2011/niaid-28.htm.
- 34.National Institute of Allergy and Infectious Diseases (NIAID). NIH discontinues tenofovir vaginal gel in 'Voice' HIV prevention study. 2011. http://www.nih.gov/news/health/nov2011/niaid-25.htm.
- 36.The IPERGAY Study. 2012. http://www.ipergay.fr/.
- 37.• Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4:151ra25. This recent article details the relationship between PrEP blood concentrations and HIV protection in the iPrEx study.CrossRefGoogle Scholar
- 38.Bangsberg D, Haberer J, Psaros C, Baeten J, Katabira E, et al. High adherence and high effectiveness observed in HIV discordant couples: Partners PrEP Study, adherence monitoring and counseling substudy. Proc. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA, 2012:Abstract 1067.Google Scholar
- 39.Donnell D, Baeten J, Hendrix C, Bumpus N, Bangsberg D, et al. Tenofovir disoproxil fumarate drug levels indicate PrEP use is strongly correlated with HIV-1 protective effects: Kenya and Uganda. Proc. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA, 2012:Abstract 30.Google Scholar
- 40.Liu A, Vittinghoff E, Irby R, Mulligan K, Sellmeyer D, et al. BMD loss in HIV– men participating in a TDF PrEP clinical trial in San Francisco. Proc. 18th Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA, 2011:Abstract 93.Google Scholar
- 41.Mugo N, Celum C, Donnell D, Campbell J, Bukusi E, et al. Pregnancy incidence and birth outcomes in a clinical trial of PrEP: Uganda and Kenya. Proc. 19th Conference on Retroviruses and Opportunistic Infections, Seattle, USA, 5–8 March 2012:Abstract 1060.Google Scholar
- 42.Antiretroviral Pregnancy Registry Interim Report, 1 January 1989 through 31 July 2011. http://www.apregistry.com/forms/interim_report.pdf.
- 43.Anderson P, Meditz A, Zheng J-H, Predhomme J, Klein B, et al. Cellular pharmacology of tenofovir and emtricitabine in blood, rectal, and cervical cells from HIV– volunteers. Proc. 19th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA, 2012:Abstract 587.Google Scholar
- 47.HIV Prevention Trials Network. HPTN 067 - The ADAPT Study: A phase II, randomized, open-label, pharmacokinetic and behavioral study of the use of intermittent oral emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis (PrEP). 2011. http://www.hptn.org/research_studies/hptn067.asp.
- 48.• U.S. Food and Drug Administration. FDA approves first drug for reducing the risk of sexually acquired HIV infection. 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm. US FDA approval of a label indication for FTC/TDF as PrEP for HIV prevention.
- 49.• World Health Organization. Guidance on pre-exposure oral prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendation for use in the context of demonstration projects, World Health Organization, Geneva. 2012. WHO guidance on next steps for implementing PrEP for HIV prevention.Google Scholar
- 50.• Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR. 2012;61:586–9. US CDC guidance on prescribing PrEP for HIV prevention in heterosexuals.Google Scholar
- 51.• Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR. 2011;60:65–8. US CDC guidance on prescribing PrEP for HIV prevention in men who have sex with men.Google Scholar
- 56.Follow on Africa Consortium for Tenofovir Studies. 2010. FACTS 001 -- Tenofovir Gel Study. http://www.facts-consortium.co.za/?page_id=83.